Oruka Therapeutics, Inc. (ORKA)

Every figure this model derived for ORKA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 873,564,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 884,559,000 AssetsCurrent 2026-06-30
current liabilities 22,968,000 LiabilitiesCurrent 2026-06-30
equity 1,114,549,000 StockholdersEquity 2026-06-30
interest expense 1,468,000 InterestExpenseNonoperating 2024-12-31
revenue 0 Revenues 2024-06-30
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ORKA on one particular measure came for.

RatioValue
current ratio38.51
current ratio reported38.51
dilution pct0.04

What to be careful about

What this model itself distrusts about ORKA's figures. Written by the derivation as it ran, not added afterwards.